DDInter1416 DDInter1840
In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Pemoline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ioflupane I-123
Ioflupane I-123 {u} (Compound) causes {v} (Side Effect) Dysgeusia
Dysgeusia {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Pemoline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Promethazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Trabectedin
Pemoline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} (Compound) causes {v} (Side Effect) Dyspnoea
Dyspnoea {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Pemoline {u} may lead to a major life threatening interaction when taken with {v} Cocaine
Cocaine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Trabectedin
Pemoline {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Iohexol {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Pemoline {u} may lead to a major life threatening interaction when taken with {v} Cocaine
Cocaine {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Pemoline may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123 and Ioflupane I-123 (Compound) causes Dysgeusia (Side Effect) and Dysgeusia (Side Effect) is caused by Trabectedin (Compound)
Pemoline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Trabectedin (Compound)
Pemoline may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Trabectedin (Compound)
Pemoline may lead to a major life threatening interaction when taken with Cocaine and Cocaine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Trabectedin (Compound)
Pemoline may lead to a major life threatening interaction when taken with Iohexol and Iohexol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Pemoline may lead to a major life threatening interaction when taken with Cocaine and Cocaine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)